News & Events

ta-Scan World Alzheimer's Day 2018 1

News Published on September 21, 2018

World Alzheimer’s Day: a Snapshot of the Indication

As today it’s World Alzheimer’s Day, let’s stop and think about the stigma related to this progressive disease which impairs the memory, along with other mental functions. More importantly, we need to break the stigma as this disease affects so many among us, not only patients but also their loved ones.

Today, Alzheimer’s Disease is the most frequent cause of dementia in the western world, with over 5,5 million patients in the USA alone and an estimated patient population of over 24 million globally.

Trial and Sponsor Activity

ta-Scan provides you with a quick overview of the current clinical research landscape, a landscape which has been evolving quite significantly in the last few years. With 525 trials currently ongoing, of which 275 started in the last two years, it’s a clear sign this disease area has not lost any awareness.

ta-Scan World Alzheimer's Day 2018 2

With many major pharmaceutical sponsors running big research trials, most trials are still in early phase research as the disease is so complicated to understand.

ta-Scan World Alzheimer's Day 2018 3

Unsurprisingly, Eli LillyRoche, and Johnson & Johnson are the top three sponsors in this domain. However, over the last years this list has expanded with some new names such as Biogen (collaborating with Eisai), Otsuka (collaborating with Lundbeck), and Cognition Therapeutics, who have shown a steep increase in clinical activity. Could one of these companies finally come with the break we’ve all been waiting for?

Sites and Investigators

ta-Scan has identified over 5000 clinical study sites and over 5500 confirmed investigators globally who are involved in enrolling patients suffering from Alzheimer’s Disease, in the hope to find a treatment for many more people.

As visualized below, the number and location of study sites and investigators indicate a high patient density distributed, not only in North America and Europe, but also in the Asia-Pacific region, reminding us of the severity of this global disease.

ta-Scan World Alzheimer's Day 2018 4

Treatments

Over the years, there have been several theories on what the perfect target for new Alzheimer’s disease drugs should be. This list has currently narrowed down to two main theories:

  1. The Tau Hypothesis, a theory which is still active. Some drug compounds to keep an eye on the following months: ABBV 8E12 (Abbvie), BIIB 092(Biogen), ACI-35 (Johnson & Johnson), and AADvac1 (Axon Neurosciences).
  2. The Amyloid hypothesis, a theory which seems to be supported by the majority of sponsors. This theory contains a long list of research drugs. However, several of these studies have had to be halted due to safety or response issues. Johnson & Johnson, with their atabecestat, is the last to join this list of halted studies. A drug that is showing promising results at the moment: Biogen and Eisai’s BAN2401, currently in phase two and interesting to keep an eye on in the future.
ta-Scan SCOPE Europe 2018 Barcelona

Events Published on September 17, 2018

SCOPE Europe 2018: Join us at the First European Edition

Join us in October at the inaugural edition of SCOPE Europe in Barcelona, Spain. Visit the ta-Scan team at booth #6 or make an appointment with our attendees:

Chairperson’s Remarks

David Cocker, Chief Scientific Officer, ta-Scan Business Intelligence Systems, MDCPartners

DAY 1, Tuesday 16 October, 13:55h
David Cocker, Chief Scientific Officer, ta-Scan Business Intelligence Systems, MDCPartners / Anju Software
Track 1: Analytics-Driven Feasibility, Site Selection and Study Activation

 

About SCOPE Europe

Building on the success of its long-running US-based counterpart, Summit for Clinical Trials Operations Executives Europe (SCOPE Europe) is a two-day event serving clinical operations executives, functional heads, category managers and those responsible for the planning and management of clinical trials in Europe and the rest of the world. The event will feature opening and closing plenary keynote sessions, three conference tracks, interactive breakout discussion groups and networking. It is an opportunity for leaders from large, mid-sized, and small pharma, specialty pharma, biotech, vendor companies, and academic research centers to come together to share best practices and discuss the new era of analytics-driven and patient-centric trials. Topics to be discussed include protocol development, global site selection, feasibility, site management, patient engagement, enrollment planning, patient recruitment, patient retention, improving site-study activation and performance, functional/full-service outsourcing and partnerships, new regulations and guideline, Risk-Based Monitoring (RBM), and improving overall quality and speed of clinical trials.

Register to join us

Have a look at the agendahttp://www.scopesummiteurope.com/2018-brochure-download-form

Register here to join us in Barcelona: https://chidb.com/reg/scoe/reg.asp

We hope to see you there!

Press Releases Published on July 18, 2018

Anju Software Continues to Build the Next Generation Life Science Software and Data Platform Through Acquisition of MDCPartners

NEW YORK–Anju Software Inc., a life sciences software platform backed by Providence Equity Partners, has acquired Antwerp-based MDCPartners, a company that specializes in business intelligence data solutions for clinical trial optimization, medical expert identification and competitive intelligence.

“MDCPartners will enable Anju to provide additional value added solutions to pharmaceutical, biotech and medical device companies. This acquisition strengthens Anju’s current product portfolio and can now provide up-to-date comprehensive data for Medical Expert Engagement and Clinical Trial Optimization. MDC, which is based in Belgium, also provides us with operations in Europe to better service our global customers,” said Mr. Kurien Jacob, CEO of Anju Software.

“Anju’s approach and philosophy provides us with financial strength and scale as well as additional resources to support our growth strategy and guide our clients over the long-term,” added Mireille De Cré, co-founder and CEO of MDCPartners.

“With the acquisition of MDCPartners, Anju continues its accelerated growth within the Medical Affairs and clinical trial sectors. Anju is now recognized as an emerging leader in the life science software industry, providing end-to-end software solutions that help customers manage mission critical pharma processes and turn data into actionable insights. We continue to be impressed with what the Anju management team, led by CEO Kurien Jacob, has been able to achieve in a short period of time,” said Gopi Vaddi, Managing Director of Providence Strategic Growth.

Snell and Wilmer acted as legal counsel to Anju and Madison Park Group acted as financial advisors to Anju on the transaction.

About Anju Software

Anju Software is a leading provider of comprehensive software solutions to the life sciences industry. The Company provides an integrated platform spanning clinical, medical affairs and after-market functions for pharmaceutical, biotech and medical device companies and clinical research organizations. Anju was founded by a group of operating professionals with deep software domain expertise and intent on building the next generation platform for the life sciences sector. Over the past two years, Anju has acquired five companies:

  • Online Business Applications – Market leader in medical information solutions and pharmacovigilance
  • OpenQ – Solutions for key opinion leader (KOL) engagement and management
  • ClinPlus – Provider of comprehensive electronic data capture (EDC), clinical trials management software (CTMS), electronic trial master file (eTMF) solutions
  • Sylogent – Clinical data capture and publishing planning solutions
  • MDCPartners – Business intelligence solutions

Anju Software is a portfolio company of Providence Strategic Growth, the growth equity affiliate of Providence Equity Partners, a global private equity firm with over $57 billion in capital under management.

About MDCPartners

MDCPartners provides business intelligence solutions for clinical trial optimization, medical expert identification and competitive intelligence. With deep expertise in the fields of data mining, semantic processing and engineering, MDC provides its clients with event-based tools to monitor and analyze an ever-expanding world of public and private data. With their proprietary data solutions, users can transform millions of scattered data points into a robust snapshot of a therapeutic area. MDC combines its expertise in drug development processes with its unique IT architecture to provide cost effective information solutions to the pharmaceutical and biotech industry. MDCPartners offers a product suite that includes: ta-Scan, a web-based data platform that helps users monitor, aggregate, and analyze regulatory data, trial data and expert profiles; normScan: web-based standards tracking tool tailored to clients’ product range; and Real World Solutions; a tool allowing the depiction of external client data merged with information from a public data cloud.

About Providence Equity

Providence is a premier global private equity firm with more than $57 billion in capital under management. Providence pioneered a sector-focused approach to private equity investing with the vision that a dedicated team of industry experts could build exceptional companies of enduring value. Since the firm’s inception in 1989, Providence has invested in more than 160 companies and is a leading equity investment firm focused on the media, communications, education and information industries. Providence is headquartered in Providence, RI, and also has offices in New York and London. For more information, please visit www.provequity.com.

Contacts

Anju Software
Kurien Jacob, +1 480-326-2358
kurien@anjusoftware.com

MDCPartners
Mireille De Cré
mireille.decre@mdcpartners.be

Providence Equity 
Sard Verbinnen & Co
Andrew Cole / Kelsey Markovich
Prov-SVC@SARDVERB.COM
+1 212-687-8080

View Business Wire press release: https://www.businesswire.com/news/home/20180621005656/en/Anju-Software-Continues-Build-Generation-Life-Science

Events Published on March 19, 2018

ta-Scan Client Testimonials at SCOPE 2018

During the SCOPE Summit in Orlando on February 12-15, 2018, we gathered some testimonials from ta-Scan clients. Learn how they leverage our clinical business intelligence platform to optimize their trial planning and feasibility.

DIA Europe 2018 ta-Scan David Cocker

Events Published on March 15, 2018

Celebrate the 30th DIA Europe with us in Basel!

The second meeting the ta-Scan team has in store for April is nothing less than the 30th edition of the DIA Europe 2018 meeting. That deserves a celebration!

Join us in Basel

If you want to get a demo of our clinical business intelligence solution ta-Scan and our newest developments, or learn more about our other (custom) software solutions, visit us at DIA Europe 2018 at booth #100 or make an appointment with the ta-Scan team:

You can register here.

DIA Europe 2018

2018 marks the 30th anniversary of the DIA EuroMeeting. To support this anniversary, and to align this European flagship meeting with all the DIA regional flagship meetings occurring across the globe, we are renaming the gathering, DIA Europe 2018. This new name reflects not only regional alignment but also a change in approach to more directly and proactively focus on the expressed needs and interests of our constituents. DIA Europe 2018 is more than just a traditional meeting. It’s a chance to learn, engage, and grow as a professional in health care.

We convene these platforms around the globe, from the DIA Global Annual Meeting in the United States, to regional meetings in China, Europe, India and Japan, to provide you with a neutral forum to discuss current issues, with the goal of uncovering new ways of working and new solutions for patients. We welcome participants from across the entire drug development industry. By incorporating representatives from the full life sciences landscape we facilitate open collaboration. We ensure that industry, payors, patients and regulators, all have an equal voice.

We look forward to welcoming everyone to DIA Europe’s home in Basel, Switzerland. Download the meeting programme here.

eyeforpharma Medical Affairs USA 2018 ta-Scan Podium

Events Published on March 15, 2018

Try out ta-Scan Podium at eyeforpharma Medical Affairs USA 2018

After what has been a very busy and successful SCOPE Summit in Orlando, the ta-Scan team is preparing for the next event: eyeforpharma Medical Affairs USA, hosted in Philadelphia, April 10-11. You can register now with code MDC200 for a $200 discount if you want to join us.

Identify Medical Experts easily with ta-Scan Podium

Next to a completely updated and optimized user interface, ta-Scan also has a new tool in store. Our mobile application ta-Scan Podium helps Medical Affairs teams and Medical Science Liaisons to identify the right Medical Experts. Have a look at how Podium works.

ta-Scan Podium Mobile Semantic Search Expert Profiling

Meet us in Philadelphia

If you want to get a demo of ta-Scan Podium and learn more about our other (custom) software solutions, visit us at eyeforpharma Medical Affairs USA 2018 at booth #12 or make an appointment with the ta-Scan team:

Register now with code MDC200 for a $200 discount.

eyeforpharma Medical Affairs USA

Medical Affairs as the change agent: bring data, authenticity and patient insight to the forefront of every decision your company makes. Eyeforpharma Medical Affairs USA 2018 (April 10-11) will bring together medical leaders and other key stakeholders from across the industry, to aid the evolution of medical in becoming the ‘home’ of value within the organisation.

Catalysts create change. The reason why the medical department is the fastest-growing department in nearly every company is because change in every other team is essential. The need for more open, science-based dialog with HCPs has never been greater; patient voices are necessarily louder and more impactful than ever; and payers require far more real world, value-based evidence. View the meeting agenda here.

SCOPE 2018 ta-Scan

Press Releases Published on February 12, 2018

MDCPartners announces 2018 innovation strategy this week at SCOPE Summit in Orlando (FL)

At the 9th annual SCOPE Summit, taking place in Orlando (Florida) this week, MDCPartners will present their two latest innovative designs to the public: ta-Scan Podium and InterSect. ta-Scan Podium is an online tablet application for Clinical Ops, Medical Affairs teams, and Medical Science Liaisons that enables users to find full profiles of all relevant Key Opinion Leaders and Key External Experts. InterSect is a desktop application that interfaces with the entire ta-Scan database on a semantic level. This unique query tool allows users to overlap internal data with the ta-Scan database and match and correlate the data in the system.

Both new innovative technologies are based on the organization’s well-known clinical business intelligence solution ta-Scan and its Semantic Search System. The patented Trial Cloud® and web mining software of ta-Scan, which is the largest semantically linked clinical database available on the web, combined with its powerful search capabilities, allow users to quickly find and analyze clinical data from multiple global public sources. The effortless delivery of in-depth and clear insights into any data point in the database is what classifies these tools as digital innovations.

This year’s SCOPE summit will focus on stimulating innovation, change, and personalized solutions to improve the clinical trial process. With hot topics such as clinical technology and innovation and artificial intelligence in clinical research, it’s important for exhibitors to stay on top of these latest developments. Where MDCPartners’ focus in the previous years was more on the introduction of new features and developments, this year it has shifted to more personalized solutions, with new modules being completely customizable to integrate private data.

“As a company which provides clinical intelligence, we believe it is crucial to gain greater insights into therapeutic area landscapes by using innovative and personalized solutions. That’s why we collaborate with our clients to answer the business questions they need. The goal of creating these new modules is not only to increase work efficiency, but also to make decision making more transparent and interoperable,” says CEO Mireille De Cré. MDCPartners will introduce the full product portfolio at the SCOPE summit and provide top pharma executives with private sessions to test and use the products live.

View GlobeNewswire press release: http://inpublic.globenewswire.com/releaseDetails.faces?rId=2168008

ta-Scan Podium Mobile Semantic Search Expert Profiling

Press Releases Published on December 22, 2017

MDCPartners Introduces Medical Expert Search Tool for Biopharma with New “ta-Scan Podium” App

MDCPartners introduces ta-Scan Podium, an online application for Clinical Ops, Medical Affairs teams and Medical Science Liaisons. The technology is based on the organization’s well-known clinical business intelligence solution ta-Scan, which effortlessly delivers in-depth and clear profiles of all relevant Key Opinion Leaders and Key External Experts. The application also categorizes these expert profiles by their medical relevance and professional credentials. The ranking is based on the experts’ past and current clinical research activity and their experience levels within various disease areas.

The growing need for a user-friendly and up-to-date database of expert profiles led to the development of ta-Scan Podium. This mobile enterprise tool compresses hours of internet searching to a few clicks.

“Increasing scrutiny how pharma engages with therapeutic leaders has created a new demand in selection and evidence-based approaches to rank KOLs by fair market value,” commented David Cocker, Chief Scientific Officer at MDCPartners. ta-Scan Podium is powered by ta-Scan’s semantic search system: a user types in some medical filters, and ta-Scan Podium returns a list of potential KOL names, their rank, and therapeutic relevance. Tapping the résumé icon reveals a full profile. The patented Trial Cloud® and web mining software of ta-Scan, which is the largest semantically linked clinical database available on the web, combined with its powerful search capabilities, allows users to quickly find and analyze clinical expert data from multiple global public sources.

This new mobile application is a milestone in the product portfolio of MDCPartners. As a company which provides clinical intelligence and consultancy, MDCPartners believes it is crucial to gain greater insights into the therapeutic area expert landscape.

ta-Scan Podium Mobile Semantic Search Expert Profiling

View GlobeNewswire press release: http://inpublic.globenewswire.com/releaseDetails.faces?rId=2157986

SCOPE 2018 ta-Scan David Cocker

Events Published on December 18, 2017

Catch up with ta-Scan during SCOPE 2018 at booth 300

On February 12-15, 2018 the ta-Scan team has its annual appointment with SCOPE 2018. Meet us in the Hyatt Regency in Orlando, Florida at booth 300 to discover what we have been working on the last year!

Find Medical Experts on the go with ta-Scan Podium

Next to a completely updated and optimized user interface, ta-Scan also has a new tool in store. Our mobile application ta-Scan Podium helps Clinical Ops, Medical Affairs teams, and Medical Science Liaisons to identify the right Medical Experts. Have a look at how Podium works.

ta-Scan Podium Mobile Semantic Search Expert Profiling

Meeting up

If you want to get an exclusive preview of Podium and learn more about our other (custom) software solutions, visit us on SCOPE 2018 at booth #300 or make an appointment with the ta-Scan team:

Summit for Clinical Operations Executives

The 9th Annual SCOPE Summit, taking place February 12-15, 2018 in Orlando, FL, will offer four stimulating days of in-depth discussions in 18 different conferences, 3 plenary keynote sessions, and the ever-popular interactive breakout discussions focused on advances and innovative solutions in all aspects of clinical trial planning, management and operations: Site Selection and Management, Patient Engagement, Recruitment and Retention, Protocol Optimization, Feasibility, Data Strategy & Analytics, Sensors and Wearables, Project Management, Outsourcing, Forecasting, Resource Management and Capacity Planning, Budgeting and Contracting, Quality (QbD) in Trial Conduct, Risk-Based Monitoring, Artificial Intelligence (AI), Post-Marketing Studies, Observational Research, Clinical Supply Chain, and Precision Medicine. View SCOPE’s programs here.

ta-Scan ASH 2017

News Published on December 8, 2017

What to expect at ASH 2017?

The 59th Annual Meeting & Exposition of the American Society of Hematology (ASH 2017) will be hosted in Atlanta from the 9th to the 12th of December 2017, for another exciting round of stimulating discussions and presentations of results in the malignant and non-malignant Hematology field.

ASH 2017 ta-Scan Abstracts

Top 10 Therapeutic Areas

Unsurprisingly, Leukemia will be the hottest topic at this year’s ASH meeting, followed by Lymphoma, Anemia and Multiple Myeloma. Other presentations will cover research about Hemorrhage, Myelodysplastic Syndromes and other Blood Coagulation Disorders, in which the interest has remained stable over the past 3 years.

ASH 2017 ta-Scan Top 10 Therapeutic Areas

Top 15 Commercial Sponsors Trials over the Last 3 Years

From a trial perspective, you can expect considerable differences in trial discussion activity compared to the past 2 years. With an increase of almost 70% in presentations about trials (427 trials in 2017, compared to 255 trials in 2015), the 59th ASH meeting has 323 new trials in store for its attendees. This trend confirms the commitment of several sponsors to stay ahead and relevant in the field of Hematology.

ASH 2017 ta-Scan Top 15 Commercial Sponsors Trials

Most impressive is the increase in trials sponsored by Roche and Johnson & Johnson. Out of the 30 trials Johnson & Johnson is sponsoring this year, half of them are researching Daratumumab in combination with other drugs in Multiple Myeloma, as well as other indications. Roche, on the other hand, is studying combination therapies with Obinutuzumab, mainly in Leukemia and Lymphoma.

ASH 2017 ta-Scan Growing Sponsors

Drugs of Interest

Burton’s Tyrosine Kinase Inhibitors (BTK Inhibitors) and CD19 CARTs are still among the preferred modes of action to target in drug development.

ASH 2017 ta-Scan Drugs of Interest

With 3 new molecules and 4 trials in Leukemia and Lymphoma, DTRM Biopharma is one of the smaller sponsors that is betting on BTK inhibitors.

Over the past few years, CD19 is also growing in importance as a target in Leukemia with CART-T therapies. With new drugs in development by ADC-Therapeutics, Kite Pharmaceuticals, and Celgene, we expect a competitive battle for market share in Leukemia.

Browse categories


Browse tags